ArticleCellular oncology (Dordrecht, Netherlands)2017

Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade.

Eun-Sun Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.